Personalized Cell Therapy Market Report 2026

Personalized Cell Therapy Market Overview

• Personalized Cell Therapy market size has reached to $20.83 billion in 2025 • Expected to grow to $56.46 billion in 2030 at a compound annual growth rate (CAGR) of 22.1% • Growth Driver: Rising Neurological Disorders Fuel Growth In The Personalized Cell Therapy Market • Market Trend: Advancements In Closed-System Manufacturing For Personalized Cell Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Personalized Cell Therapy Market?

Personalized cell therapy refers to a type of medical treatment where a patient's own cells, or cells that are specifically tailored to them, are used to treat a disease or condition. This therapy is customized to the individual's unique biological profile, often involving the modification or manipulation of cells to enhance their therapeutic potential. The key advantage of personalized cell therapy is that it minimizes the risk of rejection and adverse reactions as the therapy is designed to be compatible with the patient's own body. The main types of personalized cell therapy include lymphocytes, mesenchymal stem cells, hematopoietic stem cells, and others. Lymphocytes are a type of white blood cell that are part of the immune system and help the body fight disease. It uses various techniques such as platelet transfusions, bone marrow transplantation, packed red cell transfusions, and organ transplantation and is applied for cardiovascular diseases, neurological disorders, inflammatory diseases, diabetes, cancer, and others. It is used by various end-users, including hospitals, homecare, specialty clinics, and others.

What Is The Personalized Cell Therapy Market Growth Forecast?

The personalized cell therapy market size is expected to see exponential growth in the next few years. It will grow to $56.46 billion in 2030 at a compound annual growth rate (CAGR) of 22.1%. The growth in the forecast period can be attributed to growing demand for autologous and allogeneic cell therapies, increasing adoption of ai-driven treatment optimization, rising government and private funding for cell therapy research, expanding applications in cancer, cardiovascular, and autoimmune diseases, growing partnerships between biotech firms and research institutes. Major trends in the forecast period include increasing adoption of genomic-based cell therapy approaches, rising implementation of personalized immunotherapy techniques, growing integration of digital platforms for cell therapy management, increasing use of ai and big data in cell therapy research, rising investment in biomanufacturing and scalable cell production.

Global Personalized Cell Therapy Market Segmentation

1) By Cell Type: Lymphocytes, Mesenchymal Stem Cells (MSCs), Hematopoietic Stem Cells, Other Cell Types 2) By Technique: Cell Engineering And Expansion Techniques, Bone Marrow Transplantation, Autologous Cell Infusion Techniques, Adoptive Cell Transfer Techniques 3) By Application: Cardiovascular Diseases, Neurological Disorders, Inflammatory Diseases, Diabetes, Cancer, Other Applications 4) By End-User: Hospital, Cell Therapy Treatment Centers, Specialty Clinics, Other End-Users Subsegments: 1) By Lymphocytes: T Cells, Natural Killer (NK) Cells, Regulatory T Cells 2) By Mesenchymal Stem Cells (MSCs): Bone Marrow-Derived MSCs, Adipose Tissue-Derived MSCs, Umbilical Cord-Derived MSCs 3) By Hematopoietic Stem Cells: Autologous Hematopoietic Stem Cells, Allogeneic Hematopoietic Stem Cells 4) By Other Cell Types: Dendritic Cells, Fibroblasts, Endothelial Cells

What Is The Driver Of The Personalized Cell Therapy Market?

The rise in neurological disorders is expected to drive the growth of the personalized cell therapy market going forward. Neurological disorders are a group of conditions affecting the brain, spinal cord, and nerves, leading to symptoms such as impaired motor function, cognitive deficits, and sensory disturbances. Neurological disorders are occurring due to an aging population, environmental stressors, and lifestyle changes contributing to higher incidences of neurodegenerative diseases. Personalized cell therapy is required for neurological disorders, as it offers tailored treatments that target specific patient needs, potentially restoring damaged neural tissue and improving outcomes in complex, individualized conditions. For instance, in April 2024, according to Neurology, a US-based publication of the American Academy of Neurology, an article stated that global cases of brain disorders, also known as neurological disorders, are projected to increase by approximately 22% by the year 2050. Therefore, the rise in neurological disorders is driving the growth of the personalized cell therapy industry.

Key Players In The Global Personalized Cell Therapy Market

Major companies operating in the personalized cell therapy market are Bristol-Myers Squibb Company, GlaxoSmithKline plc, Gilead Sciences Inc., Poseida Therapeutics Inc., Sangamo Therapeutics Inc., Nkarta Therapeutics Inc., Intellia Therapeutics Inc., Tessa Therapeutics Pte Ltd, Atara Biotherapeutics Inc., Adaptimmune Therapeutics plc, Precision BioSciences Inc., Editas Medicine Inc., Cellectis S.A., Gracell Biotechnologies Inc., Mesoblast Limited, Fate Therapeutics Inc., Athersys Inc., Bellicum Pharmaceuticals Inc., Celyad Oncology SA, Century Therapeutics Inc., Gamida Cell Ltd., CRISPR Therapeutics AG, Allogene Therapeutics Inc., Bluebird bio Inc., Autolus Therapeutics plc

Global Personalized Cell Therapy Market Trends and Insights

Major companies operating in the personalized cell therapy market are focusing on innovative therapies such as closed-system sterility, which allows for contamination-free processing of patient-derived cells from collection to final formulation. Closed-system sterility refers to a method of processing cells without exposing them to the external environment, ensuring they remain sterile throughout the entire manufacturing or handling process. For instance, in March 2025, Limula SA, a Switzerland-based company specializing in advanced cell therapy solutions, launched LimONE, an automated cell therapy manufacturing platform, which marked a significant advancement aimed at streamlining the production of personalized therapies such as CAR-T and hematopoietic stem cell treatments. Additionally, it offers a closed-system sterile workflow and more reproducible patient-specific cell therapy production.

What Are Latest Mergers And Acquisitions In The Personalized Cell Therapy Market?

In March 2025, Bristol Myers Squibb (BMS), a US-based pharmaceutical company specializing in innovative medicines, acquired 2seventy bio, Inc. for an undisclosed amount. Through this acquisition, BMS aims to consolidate its personalized cell therapy capabilities, particularly in cancer treatment, by gaining full control over Abecma (idecabtagene vicleucel), a BCMA-directed CAR T therapy, thereby advancing the development and commercialization of patient-specific cell therapies. 2seventy bio, Inc. is a US-based biotechnology company that provides personalized cell therapy, specializing in engineered CAR T therapies for hematologic malignancies.

Regional Outlook

North America was the largest region in the personalized cell therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Personalized Cell Therapy Market?

The personalized cell therapy market consists of revenues earned by entities by providing services such as c car-t cell therapy, stem cell transplantation, tissue regeneration, gene editing therapies and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The personalized cell therapy market also includes sales of personalized cancer vaccines, cell therapy kits and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Personalized Cell Therapy Market Report 2026?

The personalized cell therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the personalized cell therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.